ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Janus kinase (JAK)"

  • Abstract Number: 1645 • 2015 ACR/ARHP Annual Meeting

    Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Clinical and Radiographic Efficacy in Open-Label, Long-Term Extension Studies over 7 Years

    Jürgen Wollenhaupt1, Joel Silverfield2, Eun Bong Lee3, Ketti Terry4, Kenneth Kwok5, Irina Lazariciu6, Chudy Nduaka7, Carol A. Connell4, Ryan DeMasi5 and Lisy Wang4, 1Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 2Healthpoint Medical Group, Tampa, FL, 3Seoul National University, Seoul, South Korea, 4Pfizer Inc, Groton, CT, 5Pfizer Inc, New York, NY, 6Quintiles, Saint-Laurent, QC, Canada, 7Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We report tofacitinib safety, tolerability, and clinical response over 84 months…
  • Abstract Number: 1663 • 2015 ACR/ARHP Annual Meeting

    Influence of Age and Renal Impairment on Pharmacokinetics of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor

    Namour Florence1, Liesbeth Fagard2, Annegret Van der Aa2, Sandy Goss3, Pille Harrison2 and Chantal Tasset2, 1Galapagos SASU, Romainville, France, 2Galapagos NV, Mechelen, Belgium, 3Abbvie, Chicago, IL

    Background/Purpose: Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor combining clinical efficacy and a rapid onset of action with a good safety profile…
  • Abstract Number: 1680 • 2015 ACR/ARHP Annual Meeting

    Selective JAK1 Inhibition with Filgotinib (GLPG0634) Decreases Plasma Markers of Inflammation and Joint Damage in Patients with Rheumatoid Arthritis

    René Galien1, Annegret Van der Aa2, Roland Blanque1, Sophie Darquenne1, Pille Harrison2 and Chantal Tasset2, 1Galapagos SASU, Romainville, France, 2Galapagos NV, Mechelen, Belgium

    Background/Purpose: Among the 4 Janus kinase (JAK) family members, JAK1 often has a dominant role in the intracellular signaling for cytokines involved in auto-immune and…
  • Abstract Number: 1681 • 2015 ACR/ARHP Annual Meeting

    4-Week Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor Filgotinib (GLPG0634) Changes Lipid Profile with a Preferential Increase in HDL

    René Galien1, Pille Harrison2, Reginald Brys2, Annegret Van der Aa2, Gerben van 't Klooster2 and Chantal Tasset2, 1Galapagos SASU, Romainville, France, 2Galapagos NV, Mechelen, Belgium

    Background/Purpose: Patients with active rheumatoid arthritis (RA) present low levels of lipids - total cholesterol (TC), low density lipoprotein-cholesterol (LDL-c), high density lipoprotein-cholesterol (HDL-c) and…
  • Abstract Number: 1773 • 2015 ACR/ARHP Annual Meeting

    Pan JAK Inhibitor Tofacitinib Ameliorate Autoimmunity and Nephritis in Lupus Prone Mice Via Inhibition of Interferon Signaling Pathway

    Keigo Ikeda1,2, Kunihiro Hayakawa2, Maki Fujishiro3, Mikiko Kawasaki3, Takuya Hirai2,4, Shinji Morimoto2,4, Yoshinari Takasaki5 and Iwao Sekigawa3,4, 1Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, 2Institute for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, 3Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, 4Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Chiba, Japan, 5Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

    Background/Purpose: We previously reported that Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway-mediated regulation of interferon (IFN) regulatory factor (IRF)-related genes may have an…
  • Abstract Number: 1943 • 2015 ACR/ARHP Annual Meeting

    Potent and Selective Tyk2 Inhibitors Block Th1- and Th17- Mediated Immune Responses and Reduce Disease Progression in Rodent Models of Delayed-Type Hypersensitivity and Psoriasis

    Wenyan Miao1, Craig Masse1, Jeremy Greenwood2, Rosana Kapeller1 and William Westlin1, 1Nimbus Therapeutics, Cambridge, MA, 2Schrodinger Inc., New York, NY

    Background/Purpose: Tyk2 is a member of the JAK family kinases and is a key mediator of IL-12, IL-23, and type I interferon signaling. These cytokines…
  • Abstract Number: 1945 • 2015 ACR/ARHP Annual Meeting

    microRNA-30a Promotes the Inflammatory Response of Rheumatoid Arthritis By Regulating Th1 Cell Differentiation

    Jing Zhang1, HUA YE2, Jianping Guo1, Yan Du3, Mengru Liu1 and Zhanguo Li4, 1Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, 2No.11 XIZHIMENG SOUTH STREET,, Peking University People's Hospital, Beijing, China, 3Department of Rheumatology and Immunology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China, 4Peking University People's Hospital, Beijing, China

    Background/Purpose:  In our previous study, the transcriptome profiles of CD4+T cells from 13 active RA cases and 9 healthy controls were accessed by microarrays. a…
  • Abstract Number: 2143 • 2015 ACR/ARHP Annual Meeting

    A Safety Analysis of Tofacitinib 5mg Twice Daily Administered As Monotherapy or in Combination with Background Conventional Synthetic Dmards in a Phase 3 Rheumatoid Arthritis Population

    Alan J Kivitz1, Boulos Haraoui2, Jeffrey Kaine3, Vanessa Castellano4, Eustratios Bananis4, Carol A Connell5, Elaine Hoffman5 and Liza Takiya6, 1Altoona Center for Clinical Research, Duncansville, PA, 2Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 3Sarasota Arthritis Research Center, Sarasota, FL, 4Pfizer Inc, Collegeville, PA, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, New York, NY

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In Phase 3 (P3) studies, tofacitinib demonstrated safety and efficacy…
  • Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting

    Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis

    V. Strand1, A. Dikranian2, J. Beal3, K. Kwok3, S. Krishnaswami4, S. Wood4 and C. Nduaka4, 1Biopharmaceutical Consultant, Portola Valley, CA, 2San Diego Arthritis Medical Clinic, San Diego, CA, 3Pfizer Inc, New York, NY, 4Pfizer Inc, Groton, CT

    Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…
  • Abstract Number: 1812 • 2014 ACR/ARHP Annual Meeting

    Investigation of the Sting/Interferon Pathway Activation in a Novel Vasculopathy and Pulmonary Syndrome

    Yin Liu1, Adriana Almeida de Jesus2,3, Bernadette Marrero4, Dan Yang5, Gina A. Montealegre Sanchez6, Steve Brooks7, Zuoming Deng8, Amy Paller9, Manfred Boehm5 and Raphaela Goldbach-Mansky6, 1Translational Autoinflammatory Disease Section, Office of the Clinical Director, NIAMS/NIH, Bethesda, MD, 2Translational Autoinflammatory Disease Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 3Translational Autoinflammatory Diseases Section, NIAMS/NIH, Bethesda, MD, 4Translational Autoinflammatory Disease Section, NIAMS/NIH, Bethesda, MD, 5Laboratory of Cardiovascular Regenerative Medicine, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, 6Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 7NIAMS/NIH, Bethesda, MD, 8Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 9Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose:  We have recently studied a group of patients with a prominent interferon (IFN) signature in the blood, distinct from IL-1 mediated autoinflammatory diseases. Six…
  • Abstract Number: 1537 • 2014 ACR/ARHP Annual Meeting

    Clinical Characteristics of RA Patients Newly Prescribed Tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration Approval:  Results from the Corrona US Rheumatoid Arthritis Registry

    Arthur Kavanaugh1, George W. Reed2,3, Katherine C. Saunders2, Andrew S. Koenig4, Jamie Geier5, Joel M. Kremer6, Jeffrey D. Greenberg2,7 and Clifton O. Bingham III8, 1University of California San Diego, La Jolla, CA, 2Corrona, LLC., Southborough, MA, 3University of Massachusetts Medical School, Worcester, MA, 4Pfizer, Inc., Collegeville, PA, 5Pfizer, Inc., New York, NY, 6Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 7Rheumatology, New York University School of Medicine, New York, NY, 8Johns Hopkins University, Baltimore, MD

    Background/Purpose: To provide initial characterization of the patients prescribed tofacitinib during the early period after United States (US) Food and Drug Administration (FDA) approval (11/6/2012).…
  • Abstract Number: 1514 • 2014 ACR/ARHP Annual Meeting

    An Analysis of in-Vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically-Meaningful Concentrations

    M.E. Dowty, T.S. Lin, L. Wang, J. Jussif, B. Juba, L. Li, E. Moy and J.-B. Telliez, Pfizer Worldwide R&D, Cambridge, MA

    Background/Purpose: A number of Janus kinase (JAK) inhibitors are being actively investigated for treatment of rheumatoid arthritis (RA), including tofacitinib, baricitinib, filgotinib (GLPG0634), and decernotinib…
  • Abstract Number: 1485 • 2014 ACR/ARHP Annual Meeting

    Analysis of Patient-Reported Outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá, in the Randomized Phase 2b Earth Explorer 1 Study

    Joel M. Kremer1, Gerd Burmester2, Michael Weinblatt3, Angela Williams4, Niklas Karlsson5, Alex Godwood6 and David Close7, 1Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, 2Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 3Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 4MedImmune Ltd, Cambridge, United Kingdom, 5Health Economics and Outcomes Research, AstraZeneca, Molndal, Sweden, 6Clinical Biostatics and Data Management, MedImmune Ltd, Cambridge, United Kingdom, 7Clinical Development, MedImmune Ltd, Cambridge, United Kingdom

    Background/Purpose Active RA significantly impairs health-related quality of life (HRQoL) and physical function of patients. Granulocyte-macrophage colony-stimulating factor (GM-CSF) plays a key role in macrophage…
  • Abstract Number: 1484 • 2014 ACR/ARHP Annual Meeting

    Discovery of ARN-4079 – a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis

    Hariprasad Vankayalapati1, Venkatakrishnareddy Yerramreddy1, Philip Bendele2, Alison Bendele3, Rueban Jacob Anicattu Issac4, Ram Sudheer Adluri5, Philip LoGrasso6 and Joel M. Kremer7, 1Early Discovery and Medicinal Chemistry, Arrien Pharmaceuticals, Salt Lake City, UT, 2Principal Investigator CIA models, Bolder BioPATH, Inc., Boulder, CO, 3Pathologist, Bolder BioPATH Inc., Boulder, CO, 4Biology, GVK Biosciences Private Limited., Hyderabad, India, 5GVK Biosciences Private Limited., Hyderabad, India, 6Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, 7Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY

    Background/Purpose: The Non-receptor tyrosine kinases, JAK3 and ITK are key regulators of cytokine pathways and are important clinically validated targets, which offer the potential for…
  • Abstract Number: 1483 • 2014 ACR/ARHP Annual Meeting

    Efficacy and Safety of Baricitinib in Japanese Rheumatoid Arthritis Patients during a 52 Week Extension Phase

    Yoshiya Tanaka1, Kahaku Emoto2, Zhihong Cai2, Douglas E. Schlichting3, Terence Rooney3 and William Macias3, 1University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Eli Lilly Japan K.K., Kobe, Japan, 3Eli Lilly and Company, Indianapolis, IN

    Background/Purpose Baricitinib (bari), an oral JAK1/JAK2 signaling inhibitor, was evaluated in a blinded phase 2b study for 12 weeks as a treatment for rheumatoid arthritis…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology